Preclinical evaluation of heat shock protein 90 inhibitor, IPI-504 in human pancreatic xenografts.

被引：0
|
作者：
Song, Dongweon
Jimeno, Antonio
Kulesza, Piotr
Messersmith, Wells
Zhang, Xian Feng
Bouraoud, Nadia
Pien, Christine
Tong, Jeffery
Hidalgo, Manuel
机构：
[1] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[2] Infin Pharmaceut Inc, Cambridge, MA USA
来源：
CANCER RESEARCH | 2006年 / 66卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5475
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Activity of the Heat Shock Protein 90 Inhibitor Ganetespib in Melanoma
    Wu, Xinqi
    Marmarelis, Melina E.
    Hodi, F. Stephen
    PLOS ONE, 2013, 8 (02):
  • [42] Epigenetic effects of inhibition of heat shock protein 90 (HSP90) in human pancreatic and colon cancer
    Nagaraju, Ganji Purnachandra
    Wu, Christina
    Merchant, Neha
    Chen, Zhengjia
    Lesinski, Gregory B.
    El-Rayes, Bassel F.
    CANCER LETTERS, 2017, 402 : 110 - 116
  • [43] The novel HSP90 inhibitor IPI-504 synergizes with bortezomib in mantle cell lymphoma cells by targeting both NF-kappaB signaling and unfolded protein response and leading to increased mitochondrial apoptosis
    Roue, Gael
    Perez-Galan, Patricia
    Lopez-Guerra, Monica
    Villamor, Neus
    Campo, Elias
    Colomer, Dolors
    BLOOD, 2007, 110 (11) : 478A - 478A
  • [44] Preclinical antitumor activity of SST0116CL1, a novel heat shock protein 90 (HSP90) inhibitor
    Vesci, Loredana
    Milazzo, Ferdinando
    Carollo, Valeria
    Pace, Silvia
    Giannini, Giuseppe
    CANCER RESEARCH, 2014, 74 (19)
  • [45] IPI-504, a selective inhibitor of Hsp90, exhibits potent antitumor activity against Her2 positive, Herceptin-sensitive and refractory cell lines
    Leow, Ching Ching
    Coffman, Karen
    Chesebrough, Ion
    Mao, Shenlan
    Fazenbaker, Christine
    Weng, David
    Gooya, John
    Porter, James
    Coats, Steve
    Jallal, Bahija
    Jackson, Dowdy
    Chang, Yong S.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3504S - 3504S
  • [46] Cardiovascular safety profile of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor: Results from two independent phase I trials in patients with advanced cancer
    MacRae, C.
    Richardson, P. G.
    Walker, J.
    Grayzel, D. S.
    Demetri, G. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [47] The Hexameric Structures of Human Heat Shock Protein 90
    Lee, Cheng-Chung
    Lin, Ta-Wei
    Ko, Tzu-Ping
    Wang, Andrew H. -J.
    PLOS ONE, 2011, 6 (05):
  • [48] The hexameric structures of human heat shock protein 90
    Lee, C. -C.
    Lin, T. -W.
    Ko, T. -P.
    Wang, A. H. -J.
    FEBS JOURNAL, 2012, 279 : 414 - 415
  • [49] IPI-504, a Novel, orally active HSP90 inhibitor, prolongs survival of mice with BCR-ABL T315I CML and B-ALL.
    Peng, Cong
    Brain, Julia
    Hu, Yiguo
    Kong, Linghong
    Grayzel, David
    Pak, Roger
    Read, Margaret
    Li, Shaoguang
    BLOOD, 2006, 108 (11) : 619A - 619A
  • [50] Heat shock protein 90 inhibitor ameliorates pancreatic fibrosis by degradation of transforming growth factor-β receptor
    Peng, You-Fan
    Lin, Hao
    Liu, De-Chen
    Zhu, Xiang-Yun
    Huang, Nan
    Wei, Ying-Xiang
    Li, Ling
    CELLULAR SIGNALLING, 2021, 84
12345